RANBAXY - enters anti-AIDS segment
The anti-AIDS drug market is currently dominated by the Mumbai based Cipla. Presently, Ranbaxy laboratories, the country's largest pharmaceutical company, is planning to enter the anti-AIDS drugs segment. According to Ranbaxy's regional director for India and west Asia, S D Kaul, the company is in a position to launch Lamivudine, Nevirapine, Aabacavir and Indinavir products in the Indian market s...Ranbaxy joins hand with Cipla to co-market ciprofloxacin
Two of the leading pharmaceutical industries, Ranbaxy Laboratories and Cipla announced an alliance to co-market Ranbaxy’s once-a-day formulation of Ciprofloxacin. The formulation had recently received Drug Controller General of India’s (DCGIs) approval for marketing in India. Ciproloxacin is a unique dosage form of the broad-spectrum antibiotic. The domestic market for ciprofloxacin is estimated...Ranbaxy gets US FDA approval for Lisinopril
Ranbaxy Pharmaceuticals Inc (RPI) has received a tentative approval from the US FDA for Lisinopril tablets. Lisinopril is recommended for hypertension, either alone for initial therapy or with other classes of anti-hypertenive agents. It is also used as adjunctive therapy in the management of heart failure and patients who do not respond to diuretics. // However it expects to launch...Ranbaxy Labs' Entry Into Anti-Acne Market
Ranbaxy Laboratories' entry into the global anti-acne market is likely to be delayed as the mandatory inspection by the US Food and Drug Administration (US FDA) for the company's ANDA (Abbreviated New Drug Application) for the generic isotretinoin has been postponed. The US FDAs investigator had not yet arrived. The US FDA has already approved its manufacturing facility for the produc...Ranbaxy trying to make inroads in herbal drugs market
Ranbaxy Laboratories Chairman, Tajendra Khanna, in a recent seminar organised by Guru Gobind Singh Indraprastha University on 'Managing Corporate Reputation', spoke about the comapny's plan of foraying into the herbal drugs market. He said that their products would create stiff competition for the key player in the market - Dabur, which has 60 per cent market share. The company plans to market a...